JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

394

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

November 16, 2027

Study Completion Date

April 16, 2028

Conditions

Small Cell Lung Cancer

Interventions

DRUG

JK-1201I

JK-1201I will be administered as an IV infusion at dose of 180mg/m2 on Day 1 of each 21-day cycle.

DRUG

Topotecan

Topotecan will be administered per drug label.

All Listed Sponsors

lead

JenKem Technology Co., Ltd.

INDUSTRY

NCT06581380 - JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter